CompletedPhase 2

Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens

Germany50 participantsStarted 2007-09

Plain-language summary

Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * main symptoms of allergic rhinitis/rhinoconjunctivitis with or without controlled asthma against grass pollen allergens * positive SPT * positive EAST * positive specific provocation test Exclusion Criteria: * serious chronic diseases * other perennial allergies

What they're measuring

Systemic reaction (according to Tryba)

Timeframe: uptitration phase

Trial details

NCT IDNCT00666341

SponsorAllergopharma GmbH & Co. KG

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-01

View on ClinicalTrials.gov More Type I-Allergy trials